Wall Street analysts expect Denali Therapeutics Inc (NASDAQ:DNLI) to post sales of $12.88 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Denali Therapeutics’ earnings, with the lowest sales estimate coming in at $640,000.00 and the highest estimate coming in at $35.50 million. Denali Therapeutics reported sales of $640,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 1,912.5%. The firm is scheduled to issue its next earnings report on Friday, May 10th.
According to Zacks, analysts expect that Denali Therapeutics will report full-year sales of $61.35 million for the current year, with estimates ranging from $14.75 million to $129.16 million. For the next year, analysts forecast that the business will post sales of $167.54 million, with estimates ranging from $16.00 million to $350.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Tuesday, March 12th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.90. The firm had revenue of $125.68 million during the quarter, compared to analysts’ expectations of $9.73 million. Denali Therapeutics had a negative return on equity of 7.12% and a negative net margin of 28.06%.
In other Denali Therapeutics news, COO Alexander O. Schuth sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $28.05, for a total value of $210,375.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ryan J. Watts sold 18,333 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $22.18, for a total value of $406,625.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,500 shares of company stock valued at $1,756,548. 21.20% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc lifted its stake in Denali Therapeutics by 16.3% in the fourth quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock valued at $179,000 after buying an additional 1,212 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Denali Therapeutics by 13.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,436 shares of the company’s stock worth $216,000 after purchasing an additional 1,237 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter worth approximately $41,000. Osborn Williams & Donohoe LLC raised its stake in shares of Denali Therapeutics by 40.0% during the first quarter. Osborn Williams & Donohoe LLC now owns 14,000 shares of the company’s stock worth $386,000 after purchasing an additional 4,000 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Denali Therapeutics by 207.3% during the third quarter. JPMorgan Chase & Co. now owns 10,554 shares of the company’s stock worth $229,000 after purchasing an additional 7,120 shares during the last quarter. Institutional investors own 71.36% of the company’s stock.
DNLI stock traded up $0.40 during trading on Friday, hitting $24.63. 306,457 shares of the company’s stock were exchanged, compared to its average volume of 393,271. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -63.15 and a beta of 2.04. Denali Therapeutics has a 52-week low of $12.32 and a 52-week high of $28.86.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Featured Article: How is a Moving Average Calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.